Skip to main content

Table 2 Correlation between CXCR7 expression and clinicopathological data

From: CXCR7 expression in esophageal cancer

 

CXCR7 primary tumor (ESCC)

 
 

Total

CXCR7 negative

CXCR7 positive

p-value

  

(n=87, 55%)

(n=72, 45%)

 

Median Age, years (range)

159

60.9

(36–80)

62.1

(37–93)

0.158

Sex

       
 

Female

119

70

(59%)

49

(41%)

 
 

Male

40

17

(43%)

23

(57%)

0.098

Disease Stage (UICC 7th edition)

      
 

T

1

23

15

(65%)

8

(35%)

 
  

2

33

18

(55%)

15

(45%)

 
  

3

91

47

(52%)

44

(48%)

 
  

4

12

7

(58%)

5

(42%)

0.698

 

N

0

67

36

(54%)

31

(46%)

 
  

1-3

92

51

(55%)

41

(45%)

0.873

 

M

0

158

86

(54%)

72

(46%)

 
  

1

1

1

(100%)

0

(0%)

1.000

 

G

1

4

2

(50%)

2

(50%)

 
  

2

113

60

(53%)

53

(47%)

 
  

3

42

25

(59%)

17

(41%)

0.761

Prognostic Tumor Staging (UICC 7th edition)

 

Ia°

 

19

12

(63%)

7

(37%)

 
 

Ib°

 

16

8

(50%)

8

(50%)

 
 

IIa°

 

28

14

(50%)

14

(50%)

 
 

IIb°

 

13

8

(61%)

5

(39%)

 
 

IIIa°

 

40

21

(52%)

19

(47%)

 
 

IIIb°

 

20

10

(50%)

10

(50%)

 
 

IIIc°

 

22

13

(59%)

9

(41%)

 
 

IV°

 

1

1

(100%)

0

(0%)

0.931

Bone marrow micrometastasis

      
 

Negative

61

34

(56%)

27

(44%)

 
 

Positive

34

17

(50%)

17

(50%)

0.670

CXCR7 status

      
 

LN

Negative

32

17

(53%)

15

(47%)

 
  

Positive

20

9

(45%)

11

(55%)

0.776

 

Met

Negative

6

4

(67%)

2

(33%)

 
  

Positive

8

4

(50%)

4

(50%)

0.627

CXCR4 status

      
 

PT

Negative

17

12

(71%)

5

(29%)

 
  

Positive

29

13

(45%)

16

(55%)

0.128